felodipine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
calcium channel blockers, nifedipine derivatives 1142 72509-76-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • felodipine
  • (RS)-Felodipine
  • (+/-)-Felodipine
  • flodil
  • dl-Felodipine
A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.
  • Molecular weight: 384.25
  • Formula: C18H19Cl2NO4
  • CLOGP: 5.30
  • LIPINSKI: 1
  • HAC: 5
  • HDO: 1
  • TPSA: 64.63
  • ALOGS: -4.73
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.25 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.87 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 15 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 4.40 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 11 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 25, 1991 FDA ASTRAZENECA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood creatine increased 85.78 13.89 33 9423 4557 46672049
Hyponatraemia 77.63 13.89 99 9357 101233 46575373
Drug interaction 65.85 13.89 134 9322 202960 46473646
Bradycardia 64.21 13.89 73 9383 66225 46610381
Confusional state 60.95 13.89 113 9343 159779 46516827
Acute kidney injury 43.33 13.89 125 9331 235730 46440876
Serotonin syndrome 34.85 13.89 33 9423 24187 46652419
Dizziness 32.80 13.89 146 9310 340268 46336338
Spider naevus 32.11 13.89 7 9449 123 46676483
Hyperreflexia 31.19 13.89 17 9439 5237 46671369
Hyperkalaemia 30.35 13.89 44 9412 50665 46625941
Clonus 29.32 13.89 15 9441 4065 46672541
Polyuria 28.72 13.89 18 9438 7177 46669429
Swollen tongue 27.95 13.89 32 9424 29200 46647406
Neonatal anuria 25.92 13.89 5 9451 46 46676560
Gingival hypertrophy 25.72 13.89 10 9446 1419 46675187
Nodal rhythm 23.90 13.89 10 9446 1715 46674891
Capillary disorder 23.26 13.89 5 9451 82 46676524
Hypomagnesaemia 22.40 13.89 25 9431 22185 46654421
Hallucination 21.13 13.89 37 9419 49914 46626692
Ultrasound kidney abnormal 21.02 13.89 4 9452 34 46676572
Drug ineffective 20.38 13.89 70 9386 677768 45998838
Sinus bradycardia 20.25 13.89 19 9437 13763 46662843
Accidental overdose 19.24 13.89 22 9434 20044 46656562
Pupillary reflex impaired 19.03 13.89 9 9447 2059 46674547
Vasculitis 18.43 13.89 18 9438 13693 46662913
Glomerulonephritis 18.11 13.89 8 9448 1565 46675041
Muscle twitching 17.41 13.89 18 9438 14654 46661952
Hypergammaglobulinaemia benign monoclonal 17.00 13.89 6 9450 650 46675956
Multiple organ dysfunction syndrome 16.54 13.89 34 9422 51676 46624930
Angioedema 16.45 13.89 29 9427 39313 46637293
Hypokalaemia 16.43 13.89 47 9409 87977 46588629
Vasculitic rash 16.18 13.89 7 9449 1303 46675303
Hypernatraemia 16.01 13.89 12 9444 6389 46670217
Paraesthesia 15.79 13.89 56 9400 117381 46559225
Oedema peripheral 15.69 13.89 69 9387 159637 46516969
Past-pointing 15.03 13.89 4 9452 167 46676439
Rheumatoid arthritis 14.92 13.89 16 9440 240199 46436407
Gastroduodenal ulcer 14.85 13.89 4 9452 175 46676431
Hypopnoea 14.81 13.89 8 9448 2420 46674186
Cerebellar ischaemia 14.75 13.89 3 9453 37 46676569
Neonatal respiratory failure 14.62 13.89 4 9452 186 46676420
Hypothermia 14.55 13.89 15 9441 12168 46664438
Idiopathic urticaria 14.49 13.89 4 9452 192 46676414

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dizziness 42.90 13.78 158 10373 194751 29747196
Angioedema 38.99 13.78 54 10477 34330 29907617
International normalised ratio increased 34.59 13.78 61 10470 47678 29894269
Bradycardia 34.35 13.78 73 10458 65453 29876494
Off label use 34.08 13.78 23 10508 249267 29692680
Death 33.71 13.78 46 10485 357237 29584710
Syncope 31.86 13.78 83 10448 84820 29857127
Lip swelling 31.55 13.78 30 10501 12714 29929233
Orthostatic hypotension 30.76 13.78 40 10491 23939 29918008
Daydreaming 27.15 13.78 9 10522 461 29941486
Faeces discoloured 23.99 13.78 27 10504 13919 29928028
Atrioventricular block first degree 23.56 13.78 18 10513 5670 29936277
Hyponatraemia 22.49 13.78 63 10468 67139 29874808
Liver function test abnormal 21.70 13.78 39 10492 30911 29911036
Sleep inertia 21.38 13.78 4 10527 16 29941931
Haematuria 21.26 13.78 48 10483 44786 29897161
Completed suicide 20.30 13.78 5 10526 99487 29842460
Swelling face 19.25 13.78 30 10501 21174 29920773
Gastric ulcer 19.04 13.78 25 10506 15096 29926851
Urine output decreased 18.75 13.78 20 10511 9709 29932238
Tubulointerstitial nephritis 18.65 13.78 27 10504 17864 29924083
Drug ineffective 18.42 13.78 60 10471 340327 29601620
Myalgia 17.50 13.78 63 10468 76604 29865343
Hyperkalaemia 17.48 13.78 57 10474 65953 29875994
External ear pain 16.71 13.78 3 10528 9 29941938
Confusional state 16.50 13.78 92 10439 134742 29807205
Oedema 16.07 13.78 42 10489 42951 29898996
Periodontal disease 15.88 13.78 7 10524 782 29941165
Dyspnoea 15.07 13.78 181 10350 333114 29608833
Scrotal oedema 14.34 13.78 8 10523 1481 29940466
Acute kidney injury 14.30 13.78 153 10378 273689 29668258
Ischaemic nephropathy 14.28 13.78 3 10528 24 29941923
Carbohydrate metabolism disorder 14.06 13.78 3 10528 26 29941921

Pharmacologic Action:

SourceCodeDescription
ATC C07FB02 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS, OTHER COMBINATIONS
Beta blocking agents and calcium channel blockers
ATC C08CA02 CARDIOVASCULAR SYSTEM
CALCIUM CHANNEL BLOCKERS
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
Dihydropyridine derivatives
ATC C09BB05 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and calcium channel blockers
FDA CS M0006414 Dihydropyridines
FDA MoA N0000000069 Calcium Channel Antagonists
FDA EPC N0000175421 Dihydropyridine Calcium Channel Blocker
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002121 Calcium Channel Blockers
MeSH PA D000077264 Calcium-Regulating Hormones and Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D014665 Vasodilator Agents
CHEBI has role CHEBI:35620 vasodilator
CHEBI has role CHEBI:35674 antihypertensive
CHEBI has role CHEBI:38070 antiarrhythmic agent
CHEBI has role CHEBI:38215 calcium channel blockers

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Prinzmetal angina off-label use 87343002
Angina pectoris off-label use 194828000
Raynaud's phenomenon off-label use 266261006
Hyperkalemia contraindication 14140009
Myocardial infarction contraindication 22298006 DOID:5844
Acute cerebrovascular insufficiency contraindication 29322000
Immunosuppression contraindication 38013005
Angioedema contraindication 41291007 DOID:1558
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Coronary arteriosclerosis contraindication 53741008 DOID:3393
Aortic valve stenosis contraindication 60573004 DOID:1712
Transplantation contraindication 77465005
Chronic idiopathic constipation contraindication 82934008
Hereditary angioneurotic edema contraindication 82966003 DOID:14735
Hyponatremia contraindication 89627008
Kidney disease contraindication 90708001 DOID:557
Disorder of connective tissue contraindication 105969002 DOID:65
Hypertrophic cardiomyopathy contraindication 233873004 DOID:11984
Disease of liver contraindication 235856003 DOID:409
Peripheral edema contraindication 271809000
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Hemodialysis with High-Flux Membrane contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 1.68 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-dependent L-type calcium channel subunit alpha-1D Ion channel BLOCKER WOMBAT-PK CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel BLOCKER WOMBAT-PK CHEMBL
Adenosine receptor A3 GPCR Ki 6.22 DRUG MATRIX
Cytochrome P450 2C9 Enzyme IC50 5.34 DRUG MATRIX
Voltage-dependent T-type calcium channel subunit alpha-1H Ion channel Ki 5.17 WOMBAT-PK
Aldehyde oxidase Enzyme IC50 6.52 WOMBAT-PK
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 4.43 CHEMBL
Bile acid receptor Nuclear hormone receptor IC50 5.30 CHEMBL
Cystic fibrosis transmembrane conductance regulator Ion channel ACTIVATOR Ki 8.40 IUPHAR

External reference:

IDSource
4020159 VUID
N0000148116 NUI
D00319 KEGG_DRUG
4020159 VANDF
C0015772 UMLSCUI
CHEBI:585948 CHEBI
225 PDB_CHEM_ID
CHEMBL1480 ChEMBL_ID
CHEMBL428768 ChEMBL_ID
DB01023 DRUGBANK_ID
D015736 MESH_DESCRIPTOR_UI
3333 PUBCHEM_CID
4190 IUPHAR_LIGAND_ID
4877 INN_ID
OL961R6O2C UNII
203016 RXNORM
1621 MMSL
4716 MMSL
62563 MMSL
d00231 MMSL
003602 NDDF
108535009 SNOMEDCT_US
386863007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Felodipine HUMAN PRESCRIPTION DRUG LABEL 1 0603-3581 TABLET, EXTENDED RELEASE 2.50 mg ORAL ANDA 22 sections
Felodipine HUMAN PRESCRIPTION DRUG LABEL 1 0603-3582 TABLET, EXTENDED RELEASE 5 mg ORAL ANDA 22 sections
Felodipine HUMAN PRESCRIPTION DRUG LABEL 1 0603-3583 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 22 sections
Felodipine HUMAN PRESCRIPTION DRUG LABEL 1 13668-132 TABLET, EXTENDED RELEASE 2.50 mg ORAL ANDA 17 sections
Felodipine HUMAN PRESCRIPTION DRUG LABEL 1 13668-133 TABLET, EXTENDED RELEASE 5 mg ORAL ANDA 17 sections
Felodipine HUMAN PRESCRIPTION DRUG LABEL 1 13668-134 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 17 sections
FELODIPINE HUMAN PRESCRIPTION DRUG LABEL 1 23155-048 TABLET, EXTENDED RELEASE 2.50 mg ORAL ANDA 10 sections
FELODIPINE HUMAN PRESCRIPTION DRUG LABEL 1 23155-049 TABLET, EXTENDED RELEASE 5 mg ORAL ANDA 10 sections
FELODIPINE HUMAN PRESCRIPTION DRUG LABEL 1 23155-050 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 10 sections
Felodipine HUMAN PRESCRIPTION DRUG LABEL 1 50090-2421 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 24 sections
Felodipine HUMAN PRESCRIPTION DRUG LABEL 1 50090-4808 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 19 sections
Felodipine HUMAN PRESCRIPTION DRUG LABEL 1 51407-087 TABLET, FILM COATED 2.50 mg ORAL ANDA 21 sections
Felodipine HUMAN PRESCRIPTION DRUG LABEL 1 51407-088 TABLET, FILM COATED 5 mg ORAL ANDA 21 sections
Felodipine HUMAN PRESCRIPTION DRUG LABEL 1 51407-089 TABLET, FILM COATED 10 mg ORAL ANDA 21 sections
Felodipine HUMAN PRESCRIPTION DRUG LABEL 1 53489-368 TABLET, FILM COATED, EXTENDED RELEASE 2.50 mg ORAL ANDA 24 sections
Felodipine HUMAN PRESCRIPTION DRUG LABEL 1 53489-369 TABLET, FILM COATED, EXTENDED RELEASE 5 mg ORAL ANDA 24 sections
Felodipine HUMAN PRESCRIPTION DRUG LABEL 1 53489-370 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 24 sections
Felodipine HUMAN PRESCRIPTION DRUG LABEL 1 54868-0823 TABLET, FILM COATED 2.50 mg ORAL ANDA 24 sections
Felodipine HUMAN PRESCRIPTION DRUG LABEL 1 54868-0826 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 24 sections
Felodipine HUMAN PRESCRIPTION DRUG LABEL 1 54868-5197 TABLET, FILM COATED, EXTENDED RELEASE 5 mg ORAL ANDA 24 sections
FELODIPINE HUMAN PRESCRIPTION DRUG LABEL 1 55648-411 TABLET, FILM COATED, EXTENDED RELEASE 2.50 mg ORAL ANDA 11 sections
FELODIPINE HUMAN PRESCRIPTION DRUG LABEL 1 55648-412 TABLET, FILM COATED, EXTENDED RELEASE 5 mg ORAL ANDA 11 sections
FELODIPINE HUMAN PRESCRIPTION DRUG LABEL 1 55648-414 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 11 sections
Felodipine Human Prescription Drug Label 1 57237-108 TABLET, FILM COATED, EXTENDED RELEASE 2.50 mg ORAL ANDA 19 sections
Felodipine Human Prescription Drug Label 1 57237-109 TABLET, FILM COATED, EXTENDED RELEASE 5 mg ORAL ANDA 19 sections
Felodipine Human Prescription Drug Label 1 57237-110 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 19 sections
Felodipine HUMAN PRESCRIPTION DRUG LABEL 1 58657-685 TABLET, EXTENDED RELEASE 2.50 mg ORAL ANDA 19 sections
Felodipine HUMAN PRESCRIPTION DRUG LABEL 1 58657-686 TABLET, EXTENDED RELEASE 5 mg ORAL ANDA 19 sections
Felodipine HUMAN PRESCRIPTION DRUG LABEL 1 58657-687 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 19 sections
Felodipine HUMAN PRESCRIPTION DRUG LABEL 1 59746-369 TABLET, FILM COATED, EXTENDED RELEASE 2.50 mg ORAL ANDA 22 sections